Melanotan 1

Langendonk JG, Balwani M, Anderson KE et al. (NEJM, 2015): Two multicenter, randomized, double-blind, placebo-controlled Phase 3 trials. SC implant 16 mg vs placebo every 60 days. Primary endpoint: duration of direct sun exposure without pain over 180 days. Results: 64 hours afamelanotide vs 40 hours placebo (significant improvement). Key safety findings: most common adverse effects — implant site reactions, nausea, headache, oropharyngeal pain, skin hyperpigmentation, fatigue, dizziness. No serious drug-related adverse events in the trials. Nevi darkening documented. 8-year long-term observational data from Italy (Biolcati 2015, 115 patients): sustained efficacy, favorable safety profile, quality of life maintained over years of treatment. This is the most robustly evidenced application — three Phase 3 trials, long-term real-world data, multiple national cohort studies from Europe and the US.

XLP is caused by gain-of-function ALAS2 mutations rather than FECH deficiency, but produces similar PPIX accumulation and phototoxicity. Afamelanotide has been used off-label in XLP patients with similar rationale to EPP, and some clinical programs have included XLP patients. The mechanism of protection is identical. The EMA label has been used for both EPP and XLP patients in clinical practice in Europe.

Vitiligo — autoimmune destruction of melanocytes producing depigmented patches — represents an application where afamelanotide's melanocyte-stimulating activity could theoretically drive repigmentation of affected areas. A Phase 3 trial evaluating afamelanotide combined with narrowband UVB (NB-UVB) phototherapy vs NB-UVB alone showed significantly superior and faster repigmentation in combined treatment, particularly on the face and upper extremities. This finding did not lead to a regulatory approval but establishes proof-of-concept for the vitiligo application. Some dermatologists use afamelanotide off-label in combination with NB-UVB for vitiligo in jurisdictions where it is available.

Polymorphic light eruption (PLE) is a common photodermatosis causing itchy rashes after sun exposure, affecting approximately 10-20% of the population in northern European countries. Phase 3 trials of afamelanotide for PLE prevention have been completed but the compound has not received approval for this indication. The mechanism (increased eumelanin reducing UV-triggered immune sensitization) is coherent with PLE pathogenesis. This represents a significantly larger potential patient population than EPP.

PDT uses photosensitizers that generate ROS when activated by light — the same mechanism underlying EPP phototoxicity. Pre-treatment with afamelanotide before PDT has been explored as a way to reduce the intense skin pain that accompanies PDT treatment. Phase 2 data showed promising reduction in PDT-associated pain with afamelanotide pretreatment. An additional finding in these studies: some patients reported mood improvements — noted in the Phase 2 data as unexpected and attributed to possible MC1R-mediated central effects or secondary quality-of-life improvements from reduced pain.

Afamelanotide: [Nle4, D-Phe7]-α-MSH. Full sequence: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. MW approximately 1,647 Da. Tridecapeptide (13 amino acids), same length as native α-MSH. The two substitutions explain everything about why this compound is pharmacologically useful as a drug rather than just an interesting research tool.

Norleucine at position 4 (Nle4): replaces the natural methionine residue. Methionine is susceptible to oxidative degradation — methionine sulfoxide formation is a primary mechanism of α-MSH inactivation in vivo. Replacing it with norleucine (chemically similar but sulfur-free) eliminates this vulnerability and dramatically increases metabolic stability. D-Phenylalanine at position 7 (D-Phe7): replaces natural L-phenylalanine. The D-amino acid (mirror image configuration) changes the peptide backbone geometry in the binding region. This conformational change increases receptor-binding affinity and potency by approximately 100-1,000 fold compared to native α-MSH in bioassays, while also protecting the peptide from many proteolytic enzymes that preferentially cleave L-amino acid sequences.

The free-injection form (research chemical, SubQ): plasma half-life approximately 33 minutes from the rapid absorption and distribution phase (Dorr et al., 1996 — the Arizona clinical PK studies). This is the form community users inject. Tmax approximately 30-60 minutes. Rapid clearance means multiple injections per day or day-on/day-off protocols are used in community settings to maintain melanogenic stimulation. Oral bioavailability: essentially zero — the peptide is degraded in the gastrointestinal tract; this is an injectable-only compound for any meaningful effect.

The SCENESSE controlled-release implant (approved form): the 16 mg implant is a bioresorbable rod approximately 1.7 cm long and 1.45 mm in diameter, composed of afamelanotide admixed with poly(DL-lactide-co-glycolide) (PLGA) polymer matrix. As the PLGA degrades hydrolytically, afamelanotide is released slowly over approximately 60 days. The apparent half-life from the implant is approximately 15 hours (FDA prescribing information). Tmax from implant: median 36 hours post-implantation. For most subjects (9/12 in the FDA PK study), the last measurable plasma concentration was at 96 hours post-dose — meaning measurable drug persists for approximately 4 days while melanogenic effects (eumelanin synthesis that was already initiated) persist much longer due to the biological cascade that has been triggered.

The tanning effect from afamelanotide follows a specific biological timeline that community users frequently misunderstand. MC1R activation → cAMP increase → PKA activation → CREB phosphorylation → MITF (Microphthalmia-associated Transcription Factor) upregulation → tyrosinase transcription → eumelanin synthesis. This cascade takes time. Visible skin darkening typically begins 2-5 days after the first injection or implant, with peak tan developing over 2-4 weeks. Unlike a spray tan or UV tan (which is immediate and superficial), the afamelanotide-induced tan requires melanocytes to synthesize new melanin and distribute it through melanosomes — a real biological process. Peak pigmentation persists for weeks to months. Fading back to baseline after stopping takes 1-3 months as the melanin cycles out with normal skin cell turnover. Community users expecting rapid visible results in the first 48 hours will not see them.

Afamelanotide binds four of the five melanocortin receptors: MC1R (very high affinity — primary target; melanocytes, skin), MC3R (lower affinity; energy balance, anti-inflammatory), MC4R (lower affinity; hypothalamus, feeding behavior, sexual function), MC5R (lower affinity; exocrine glands, immune function). The MC1R binding affinity is substantially higher than affinity at MC3R, MC4R, and MC5R. At clinical doses (16 mg implant over 60 days), the dominant pharmacological effect is MC1R-mediated melanogenesis. At higher research chemical doses used by some community members, MC4R and MC3R effects (mild appetite suppression, nausea, flushing) can emerge. The MC4R activity is substantially less pronounced with MT1 than with MT2 (melanotan 2), which is a cyclic heptapeptide with much higher MC4R binding affinity — this is why MT2 causes spontaneous erections, pronounced nausea, and strong appetite suppression while MT1 generally does not.

MC1R is a G-protein coupled receptor (Gs class) expressed primarily on melanocytes — the specialized skin cells that synthesize melanin and transfer it via melanosomes to surrounding keratinocytes. In normal sun exposure, UV-induced DNA damage triggers local keratinocyte cytokine release that activates melanocytes. Afamelanotide bypasses this entirely. Receptor binding activates adenylate cyclase → cAMP elevation → protein kinase A (PKA) activation → phosphorylation of CREB (cAMP response element-binding protein) → MITF (Microphthalmia-associated Transcription Factor) upregulation → transcription of tyrosinase, TRP-1, TRP-2, and other melanogenic enzymes. The result is a coordinated upregulation of the entire eumelanin synthesis pathway.

The eumelanin/pheomelanin distinction matters. Native α-MSH typically shifts the melanin type produced toward eumelanin (brown/black) and away from pheomelanin (red/yellow). Afamelanotide, as a potent MC1R agonist, drives this shift strongly. Eumelanin is the photoprotective form of melanin — it absorbs UV and visible light broadly, scatters photons, quenches free radicals, and acts as a true optical filter. Pheomelanin, conversely, can generate ROS under UV, potentially contributing to DNA damage. This eumelanin selectivity is pharmacologically important in the EPP context — the protective effect against PPIX-generated ROS is mechanistically dependent on eumelanin's quenching capacity, not just its light absorption.

In EPP, PPIX in the skin absorbs visible light in the Soret band (400-410 nm) and undergoes photosensitization, generating singlet oxygen and other reactive oxygen species that cause microvascular injury and the characteristic burning pain. Eumelanin provides protection through multiple mechanisms simultaneously: broad-spectrum light absorption (including the Soret band wavelengths that activate PPIX); physical scattering of photons before they reach deeper dermal PPIX-containing cells; direct antioxidant activity quenching ROS before they accumulate to the threshold that triggers pain. This is not photoprotection in the same sense as sunscreen (which primarily blocks UV). It is a broad-spectrum optical and antioxidant shield that specifically addresses the photosensitization pathway in EPP.

MC1R is expressed not only on melanocytes but on immune cells, keratinocytes, and vascular endothelium. MC1R activation in these cells has been linked to anti-inflammatory signaling: suppression of NF-κB-dependent inflammatory cytokine production; reduction of TNF-α, IL-1β, and IL-6 in activated macrophages; upregulation of anti-inflammatory mediators including IL-10. In EPP, the phototoxic reaction involves an inflammatory component beyond the oxidative injury — MC1R's anti-inflammatory activity may contribute to the clinical benefit alongside the optical shielding effect. This mechanism is Grade C-D (preclinical; relevant mechanistic evidence; not the primary clinical rationale).

EPP patients have significant hepatic PPIX accumulation and approximately 5% develop severe hepatic disease that can progress to liver failure. A 2023 study (PMC10143433) found that afamelanotide treatment was associated with a dose-dependent protective effect from liver damage in EPP patients — reduced liver enzymes and hepatic PPIX markers. The mechanism is not fully characterized but likely involves reduction in PPIX-induced oxidative stress in hepatocytes through the same antioxidant signaling pathways active in skin. This is a clinically meaningful benefit for EPP patients beyond sun tolerance.

Form: solid white bioresorbable rod, approximately 1.7 cm x 1.45 mm. Contains 16 mg afamelanotide in PLGA polymer matrix. Administration: subcutaneous implantation by a trained healthcare professional into the abdomen or upper arm. Frequency: every 2 months (updated EMA label September 2025 — previously maximum 4 implants per year, now removed the annual cap). The implant procedure requires training to place correctly — it is not a standard needle injection. The implant site may be sore for several days post-placement. The implant is completely bioresorbable — no retrieval required. The implant releases drug slowly over approximately 60 days, maintaining low-level continuous MC1R stimulation rather than producing the concentration peaks of free injection.

The community form is lyophilized afamelanotide/NDP-MSH powder purchased from research chemical vendors. Reconstituted with bacteriostatic water. Administered subcutaneously via insulin syringe. The community dosing protocols are NOT equivalent to the SCENESSE implant protocol and should not be assumed to carry the same safety profile, efficacy data, or monitoring requirements.

Protocol

Dose

Frequency

Notes

Loading phase (community)

0.5–1 mg/injection

Daily for 1-2 weeks

Builds melanogenic cascade; some UV exposure alongside to enhance result

Maintenance (community)

0.5–1 mg/injection

Every 2-3 days

Maintains pigmentation; less frequent than loading

Conservative start

0.25–0.5 mg

Alternate days

Recommended for first-time users; assess side effect profile before escalating

Reference: Arizona Phase 1 clinical trials

0.08–0.21 mg/kg/day

Daily x 10 days

Academic reference dose; ~5.6–14.7 mg/day for 70 kg adult — far higher than most community protocols

Reconstitution: bacteriostatic water (not sterile water) is preferred for multi-dose use due to benzyl alcohol preservative reducing bacterial growth. Standard dilution: 2 mL bacteriostatic water per 10 mg peptide = 5 mg/mL = 5,000 mcg/mL. A 1 mg dose = 0.2 mL = 20 units on an insulin syringe. Storage: lyophilized powder at -20°C (freezer); reconstituted solution at 4°C (refrigerator) for up to 4 weeks; do not freeze reconstituted solution. Do not agitate vigorously — peptide bonds are sensitive to mechanical shearing. Swirl gently to dissolve, do not shake. Temperature during shipping is a quality concern — lyophilized powder ships at ambient if properly sealed, but reconstituted solution requires cold chain.

Site: abdomen subcutaneous fat, pinched away from muscle. Standard insulin-syringe technique. Injection at 45-degree angle into pinched fat. Hold for 5-10 seconds before withdrawing. Community commonly reports mild injection site irritation, redness, or itching at the injection site for 24-48 hours. These are typical for subcutaneous peptide injections and do not indicate a serious reaction. A warm firm nodule at the injection site (lipohypertrophy) can develop with repeated injection into the same site — rotate sites. Anaphylaxis has been reported in post-market surveillance with SCENESSE — the prescribing information warns that serious hypersensitivity reactions have been documented. A test dose in new users is prudent.

The tanning effect does not require UV exposure to be initiated — MC1R activation drives eumelanin synthesis independently of UV, which is the entire EPP therapeutic rationale. UV exposure is not required. However, UV exposure enhances and accelerates the visible tanning result: UV activates keratinocytes to release melanocyte-stimulating signals through the p53 pathway, additive with afamelanotide's MC1R stimulation. In practical terms: the tan develops faster and darker with low-level UV alongside afamelanotide than without. Most community protocols include 10-20 minutes of natural sunlight or low-session tanning bed exposure to accelerate results. This is optional, not mandatory. Users with fair skin who are also increasing their sun exposure during an MT1 protocol must account for increased UV damage even if they are now less likely to burn visibly — the eumelanin provides optical protection but does not eliminate UV DNA damage risk entirely.

The melanogenic response to afamelanotide is not acutely dose-dependent after MC1R saturation — it follows the biology of melanin synthesis, which has its own rate-limiting steps (tyrosinase enzyme kinetics, melanosome trafficking). Once MC1R is sufficiently activated, additional afamelanotide beyond what saturates the receptor produces diminishing returns for melanogenesis. The half-life of approximately 33 minutes for free injection means drug concentrations drop quickly, but the downstream melanogenic cascade that has been triggered persists for hours after drug clearance. Daily or every-other-day dosing is sufficient to maintain cumulative melanogenic stimulation.

Most common adverse reactions with SCENESSE in clinical trials (incidence >2%): implant site reaction (pain, erythema, induration); nausea; oropharyngeal pain; cough; fatigue; dizziness; skin hyperpigmentation beyond expected tanning; somnolence; respiratory tract infection. Serious adverse events in trials: none determined to be drug-related. Discontinuation rate: very low — consistent with a drug providing significant benefit in a condition with limited alternatives. The overall safety profile in controlled EPP trials over 8+ years of long-term observational data is favorable. This data is from patients who: had confirmed EPP diagnosis; received pharmaceutical-grade compound; had physician-administered implantation; underwent twice-yearly full-body skin examination; were specifically monitored for nevi changes.

NEVI DARKENING — THE MONITORING REQUIREMENT THE COMMUNITY OMITS

The SCENESSE prescribing information under Warnings and Precautions states: 'Skin Monitoring: SCENESSE may induce darkening of pre-existing nevi and ephelides due to its pharmacological effect. A regular full body skin examination (twice yearly) is recommended to monitor all nevi and other skin abnormalities.' This is not an academic precaution — afamelanotide drives MC1R-mediated melanogenesis in ALL melanocyte-containing structures in the skin, including nevi (moles). In a 2021 dermoscopic study (Arisi et al., Photochemical and Photobiological Sciences), 15 EPP patients with 103 assessed nevi were monitored during two afamelanotide implant cycles. All reticular and 2-component nevi showed focal network thickening at 5 months (T1) that returned to baseline by 12 months (T2). The authors concluded these changes were transient and physiologically normal — not carcinogenic features. The same paper cautioned that long-term safety of afamelanotide treatment needs further investigation and that the role of afamelanotide in promoting the growth of an already-present melanoma remains unaddressed. The community cosmetic use population: no baseline skin examination, no follow-up dermatological monitoring, no assessment of whether pre-existing dysplastic nevi were present before starting.

Three sources of evidence must be weighed honestly against each other. First: The Biolcati 2015 long-term observational study argued that MC1R pathway activation is inversely associated with melanoma risk — low-activity MC1R variants (found in red-haired, fair-skinned individuals who tan poorly) are associated with higher sporadic melanoma risk, while high MC1R activity (the state afamelanotide induces) is associated with eumelanin dominance, which provides some photoprotective benefit and is not melanoma-promoting per current molecular understanding. This argument suggests MC1R agonism itself is not oncogenic. Second: Arisi 2021 found that nevi changes during afamelanotide treatment in monitored patients were transient and did not show dermoscopic features associated with malignancy. Third: Habbema et al. (International Journal of Dermatology, 2017) reviewed unregulated melanotan use and documented 4 case reports of melanoma emerging from existing nevi during or shortly after unregulated melanotan use. The review noted that these cases were confounded by: unregulated (non-pharmaceutical-grade) products potentially containing unknown compounds; UV-seeking behavior common in cosmetic tanning users; inability to establish causality from case reports alone.

The honest conclusion: there is no controlled evidence that pharmaceutical-grade afamelanotide at therapeutic doses causes or promotes melanoma in individuals without pre-existing melanocytic pathology. The MC1R biology does not support a melanoma-promoting mechanism for the approved compound. However, afamelanotide stimulates melanocytes broadly — including any that may harbor pre-existing mutations. In a person with undetected dysplastic nevi, early-stage melanoma, or strong melanoma risk factors (family history, multiple atypical moles, prior melanoma), stimulating those melanocytes without dermatological monitoring is not an acceptable risk. This is why the FDA label requires twice-yearly full-body skin examination. This is why active cutaneous malignancy is a contraindication.

ACTIVE MALIGNANCY — CONTRAINDICATION FOR MELANOMA AND SKIN CANCERS

Active melanoma: absolute contraindication. Active non-melanoma skin cancer: strong caution, contraindicated per the SCENESSE prescribing information as a precautionary measure. Personal history of melanoma: full dermatological assessment mandatory before use; high-risk individuals should not use afamelanotide outside formally monitored clinical settings. Family history of melanoma combined with multiple atypical nevi: same caution. The Biolcati 2015 framing that 'MC1R signaling is not melanoma-promoting' should not be read as clearance for use in individuals with active or recent melanocytic pathology. The FDA's precautionary contraindication exists for a reason.

The SCENESSE prescribing information warns: 'Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of SCENESSE.' Anaphylaxis risk with any protein/peptide compound is real. Community users self-injecting without emergency intervention capacity should be aware of this risk. A test dose of 0.1-0.2 mg before full dosing allows observation for hypersensitivity reactions. Signs: rash, hives, difficulty breathing, swelling of face/throat, rapid heartbeat, dizziness. Have epinephrine available or ensure someone is present at first injection.

Not studied in pregnancy. Not indicated for use in pregnancy or lactation. The FDA label does not establish safety in pregnant women. No use during pregnancy.

Community users with very fair skin (Fitzpatrick Type I-II) are most likely to seek cosmetic tanning with MT1 and simultaneously most likely to respond robustly to afamelanotide. The paradox: as their skin darkens through afamelanotide use, they may feel less susceptible to UV damage and increase sun exposure beyond what is safe. Eumelanin provides real but partial UV protection — it does not make the skin invulnerable to UV DNA damage. Users should not use visible darkening as a proxy for UV safety.

The Phase 2 PDT studies using afamelanotide as a pretreatment noted an unexpected finding: patients reported mood improvements during treatment. The mechanism is not established — possible MC1R-mediated central signaling (MC1R is expressed in brain regions involved in mood regulation), possible secondary improvement from reduced pain in EPP patients, possible MC3R/MC4R effects at higher doses. Community users occasionally report subtle mood brightening, mild increase in motivation, and improved sense of wellbeing with MT1 use. This is mechanistically plausible and less disruptive than the behavioral effects of MT2 (which drives strong appetite suppression and libido/erection effects via MC4R). Grade E (community consensus) for mood effect; Grade B for the PDT clinical observation.

The cosmetic tanning use context creates psychological risks specific to skin-focused communities. Tanning obsession — a documented phenomenon, sometimes termed tanorexia — involves progressive escalation of tanning behaviors driven by distorted body image where adequate tanning never feels sufficient. MT1's cosmetic use sits in this risk environment. The pharmacological efficacy of MT1 (real, deep, even tan with minimal UV) could interact with body image preoccupation in a way that: normalizes the use of injectable research chemicals for purely cosmetic outcomes; reduces perceived cost/risk because MT1 appears 'cleaner' than MT2; creates dose escalation as users seek darker or faster results. The behavioral escalation risk is low in terms of physiological dependence — afamelanotide does not activate dopaminergic reward circuitry directly. The cosmetic escalation risk (seeking darker tan, combining with UV, continuous use, ignoring mole changes because they perceive them as 'just tanning') is the pattern to watch for.

The community's knowledge that SCENESSE is FDA-approved for EPP creates a specific misread: if it's FDA-approved, it must be safe for my use. This conflation ignores that FDA approval is specific to a disease indication, a patient population, an administration form, a dose and schedule, and a monitoring infrastructure. SCENESSE's approval does not extend safety conclusions to: self-injection of research chemical powder; cosmetic use in healthy adults; use without baseline dermatological screening; use without twice-yearly skin monitoring. The safety data from the EPP clinical program describes monitored patients in a disease context. It does not describe safety in unmonitored cosmetic users.

MT1 (afamelanotide): linear tridecapeptide (13 amino acids), [Nle4, D-Phe7]-α-MSH. MW ~1,647 Da. FDA-approved. Clinuvel pharmaceutical development. MC1R-selective. MT2 (melanotan II): cyclic heptapeptide (7 amino acids in a ring structure), Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. MW ~1,024 Da. Not FDA-approved. Never advanced to approval. Non-selective melanocortin agonist with high MC4R affinity. The cyclic ring structure of MT2 makes it more conformationally rigid, more resistant to degradation, and more potent at MC4R than the linear MT1. The shorter sequence also means MT2 crosses the blood-brain barrier more readily, explaining its strong CNS effects.

Feature

MT1 / Afamelanotide

MT2 / Melanotan II

Structure

Linear tridecapeptide, 13 AA

Cyclic heptapeptide, 7 AA

Primary receptor

MC1R (selective)

MC1R + MC3R + MC4R (non-selective)

Tanning effect

Strong; more gradual

Strong; faster onset

Nausea/vomiting

Mild; less common

Significant; often dose-limiting

Spontaneous erection

Minimal (low MC4R)

Common; can be prolonged (priapism)

Appetite suppression

Minimal

Significant MC4R-mediated

Libido effects

Minimal

Strong; used for this effect

CNS mood effects

Mild, possible mood brightening

Strong; anxiety, agitation, altered behavior

FDA approval

Yes — EPP (SCENESSE)

No — research chemical only

Melanoma case reports

4 (unregulated use; cannot establish causality)

Multiple (confounded by UV-seeking behavior)

Users researching 'tanning peptides' encounter both compounds and frequently read community advice suggesting MT1 is 'MT2 but milder.' Acting on this framing, a user expecting MT2's effects but wanting less nausea may under-dose MT1 (since MT2 is dosed in micrograms for its CNS effects, while MT1's meaningful dose range is substantially higher) and see limited tanning. Alternatively, users expecting MT1's clean profile may purchase what is labeled MT1 from an unvalidated vendor and receive MT2. Without mass spectrometry testing, the community user cannot verify what they are injecting. The two compounds have different dose ranges, different injection timing considerations, and different monitoring requirements for their different side effect profiles.

SCENESSE's FDA approval is specifically for EPP — not for cosmetic tanning. The approval does not validate cosmetic tanning as a legitimate use. The community's framing of MT1 as 'the FDA-approved tanning peptide' is misleading: it conflates an orphan drug approval for a rare disease with endorsement of the cosmetic application. An FDA-approved compound used for an unapproved indication in an unmonitored setting is not in any meaningful sense operating under the FDA's safety umbrella.

• Tan onset 3-7 days after first injection; peak darkening at 2-4 weeks; affects the entire body evenly, including areas not exposed to UV — 'uniform tan without sun' is the characteristic experience.
• Freckles and existing moles typically darken first and most visibly — a predictable melanogenic response; can be alarming to users who do not expect it; dermatological baseline needed before starting.
• Mild nausea and facial flushing for 30-120 minutes after injection — most common side effect; reduced by taking with food, lower starting dose, evening injection timing; substantially less severe than MT2.
• Mild fatigue or somnolence in the hours after injection — MC receptor-mediated; some users time injections for evening to minimize functional impact.
• Tan fades gradually over 1-3 months after stopping — biological pigmentation cycle; not a permanent effect; darker skin phototypes retain tan longer than fair phototypes.
• Small UV exposure (10-20 min sunlight) accelerates and deepens the tan result — not required but widely reported to enhance outcome.

MT1/NDP-MSH research chemical is available from multiple online vendors at prices substantially lower than SCENESSE. The community peptide market for MT1 has the same quality infrastructure challenges as all research chemical peptides: HPLC purity testing verifies absence of major impurities but does not confirm identity (you need mass spectrometry for sequence confirmation), does not test for biological activity, and does not test for endotoxin. An HPLC certificate showing 99% purity could be 99% pure MT2 or 99% pure truncated MT1 sequence — neither HPLC test would distinguish this from authentic MT1 without MS. The Habbema 2017 review specifically noted that unregulated melanotan products 'may contain other melanotropic agents or unidentified harmful components' as a confounding factor in the melanoma case reports. Vendor selection should require both HPLC and mass spectrometry confirmation of sequence identity.

The approved EPP use includes: physician-administered implantation, baseline full-body skin examination, twice-yearly follow-up skin examinations, monitoring for nevi changes, dermoscopic assessment when nevi change. The community use includes none of this. The minimum responsible analog in a community setting: full-body skin examination by a dermatologist before starting; photography or dermoscopy of all significant moles at baseline; follow-up dermatological examination if any mole changes character during or after use; personal and family melanoma history assessment before starting. This is not excessive caution for a compound that the FDA's prescribing information requires twice-yearly dermatological monitoring for in its approved, medically supervised use.

Many community users cycle MT1 seasonally: loading phase in spring, maintenance through summer, stopping in autumn. The biological pigmentation fades naturally over winter. This pattern reduces cumulative MC1R stimulation versus year-round use and is consistent with the body's natural seasonal pigmentation cycle. Whether cycle length affects nevi biology long-term is not established. The approved EPP use has moved toward year-round continuous use (every 2 months, now without annual limit per September 2025 EMA label amendment) given that EPP patients benefit from maintained photoprotection year-round. Community users with cosmetic goals and lower disease burden are better served by seasonal cycling.

Community users increasing sun exposure while on MT1 are at lower risk of vitamin D deficiency. EPP patients, conversely, often have severe vitamin D deficiency from chronic sun avoidance, which typically improves substantially on MT1 treatment (Wensink 2020 JAMA Dermatology documented improved vitamin D levels in US EPP cohort). Community users should not assume MT1-enhanced tanning fully addresses vitamin D status — direct supplementation is straightforward and more reliably effective.

The Phase 3 vitiligo data established that MT1 + narrowband UVB produced superior repigmentation versus NB-UVB alone. For community users interested in vitiligo applications (the second most common off-label community use after cosmetic tanning), this combination has the strongest evidence. Should be supervised by a dermatologist given the clinical monitoring requirements.

No pharmacological interaction evidence. BPC-157 and TB-500 work on tissue repair and angiogenesis at wound sites; MT1 works on melanocyte signaling throughout the skin. These are mechanistically independent. Community users sometimes combine them in aesthetic protocols — no controlled data on the combination, no known negative interaction.

Some community users use MT1 for tanning (MC1R-selective) and add PT-141 (bremelanotide — a different melanocortin analog approved for HSDD in women, with MC4R activity for sexual function) to achieve the libido effect that MT1 does not provide. This is a more pharmacologically rational combination than MT2 alone, since it separates the tanning and sexual function effects onto compounds that are each more selective for their respective purposes. PT-141 is FDA-approved; MT1 as research chemical is off-label. No drug interaction concerns are established.

Langendonk JG, Balwani M, Anderson KE, et al. (2015). Afamelanotide for Erythropoietic Protoporphyria. New England Journal of Medicine. 373(1):48-59. PMC4780255. [The pivotal Phase 3 RDBPC trials; n=94 (trial 1) and n=93 (trial 2); 16 mg SC implant; significant increase in pain-free sun exposure; foundation of FDA/EMA approval]

Wensink D, Wagenmakers MAEM, Barman-Aksözen J, et al. (2020). Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice. JAMA Dermatology. 156(5):570. PMC7081144. [Real-world cohort; n=117; +6 hours/week outdoors; QoL from 31% to 74%; real-world effects larger than trial; good long-term safety]

Biolcati G, Marchesini E, Sorge F, et al. (2015). Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. British Journal of Dermatology. 172(6):1601-12. [Italy; 8-year observational; sustained efficacy and safety; nevi monitoring; MC1R molecular arguments against melanoma-promoting activity]

Arisi M, Rossi M, Rovati C, et al. (2021). Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide. Photochemical and Photobiological Sciences. 20(2):315-320. [n=15 EPP patients, 103 nevi; transient network thickening at 5 months returns to baseline by 12 months; MC1R stimulation induces only physiological nevi changes; active melanoma promotion not supported]

Habbema L, Verhagen R, Van Haselen R, Bake M. (2017). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology. 56(10):975-980. [4 melanoma case reports temporally associated with unregulated melanotan use; confounded by UV-seeking behavior and product quality; review of unregulated MT1/MT2 risks]

FDA CDER. Application Number 210797Orig1s000 — Multi-Discipline Review. SCENESSE (afamelanotide) implant. October 8, 2019. [Complete FDA pharmacology, safety, and efficacy review; 100-1,000x potency vs native α-MSH; MC1R mechanism; EPP pivotal trial assessment]

SCENESSE (afamelanotide) implant Prescribing Information. Clinuvel Inc. 2024 revision. [Nevi darkening warning; twice-yearly skin exam requirement; hypersensitivity/anaphylaxis warning; pharmacokinetics from implant — Tmax 36 hr, apparent t1/2 15 hr]

Dorr RT, Lines R, Levine N, et al. (1996). Skin pigmentation and pharmacokinetics of melanotan-I in humans. Life Sciences. 58(20):1777-84. PMID 9113347. [Phase 1 Arizona PK study; SC half-life 0.8-1.7 hr beta phase; complete SC bioavailability; tanning effect visible up to 3 weeks post-10-dose regimen]

Seidl-Philipp M, et al. (2026). Afamelanotide improves quality of life and light tolerance in Austrian EPP patients. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. [Recent Austrian real-world cohort; n=20; confirms effectiveness and safety; QoL improvements sustained]

Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert Review of Clinical Pharmacology. 2021. DOI: 10.1080/17512433.2021.1879638. [Comprehensive review of chemistry, PK, preclinical and clinical data; expert opinion on afamelanotide as first effective EPP treatment]

• This compound is appropriate for: EPP patients under medical supervision (the approved indication). Off-label use by individuals who: have had a full-body dermatological assessment, have no personal or significant family history of melanoma, have no active cutaneous malignancy, understand the nausea and flushing side effect profile, source pharmaceutical-grade or verified-identity research chemical with HPLC + mass spectrometry COA, and commit to dermatological follow-up.
• This compound is not appropriate for: anyone with active melanoma or skin cancer; anyone with multiple dysplastic nevi without prior dermatological assessment; anyone expecting it to function identically to MT2 for libido/CNS effects; anyone conflating FDA approval for EPP with safety approval for cosmetic use; anyone unwilling to do baseline and follow-up skin monitoring.

• 'MT1 is just MT2 but milder': MT1 is a different compound — different sequence, different receptor profile, different clinical history, different side effect pattern. MC1R-selective vs non-selective. Not a dosage variation of MT2 — a different molecule.
• 'FDA-approved means safe for my cosmetic use': FDA approval for EPP is specific to that indication, population, administration form, and monitoring infrastructure. It does not validate cosmetic use. The monitoring requirements in the FDA label exist because the FDA did not believe they were unnecessary.
• 'The nevi darkening is just cosmetic, not a real concern': the FDA put it in the Warning and Precautions section of the prescribing information, not the cosmetic effects section. Nevi darkening requires twice-yearly full-body skin examination per the approved label. Take it seriously.
• 'MC1R biology is protective against melanoma, so there is no concern': the general biology does not override individual risk from pre-existing melanocytic pathology. The protective framing is about population-level MC1R activity vs. sporadic melanoma risk, not about using an MC1R agonist in a person with existing dysplastic nevi.

— End of Melanotan 1 / Afamelanotide —

THE PEPTIDE BIBLE | Melanotan 1 (Afamelanotide) | For Research & Educational Purposes Only